Advancing crush syndrome management: the potent role of Sodium zirconium cyclosilicate in early hyperkalemia intervention and survival enhancement in a rat model.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. CK/Albumin and K/Ca ratios as predictors of clinical severity and renal replacement therapy in pediatric crush syndrome.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2025
   Article
2. Cardiovascular events in crush syndrome: on-site therapeutic strategies and pharmacological investigations.Frontiers in pharmacology · 2024
   Review
3. Development and internal-external validation of a risk prediction nomogram for secondary myocardial injury in traumatic brain injury.Frontiers in neurology
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

11 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as